More on Myriad Genetics (MYGN): FQ3 beats across the board on a 12% Y/Y increase in revenue....

|About: Myriad Genetics, Inc. (MYGN)|By:, SA News Editor

More on Myriad Genetics (MYGN): FQ3 beats across the board on a 12% Y/Y increase in revenue. Molecular diagnostic testing revenue rose +20% over the prior year, while revenue from its BRACAnalysis test, which represented 74% of total revenue, grew by 9%. Operating income +26%, while operating margin rose to 37% from 35.5%. Shares +2.5% AH.